دورية أكاديمية
Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY analysis.
| العنوان: | Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY analysis. |
|---|---|
| المؤلفون: | Rossing, P., Anker, S.D., Filippatos, G., Pitt, B., Ruilope, L.M., Birkenfeld, A.L., McGill, J.B., Rosas, S.E., Joseph, A., Gebel, M., Roberts, L., Scheerer, M.F., Bakris, G.L., Agarwal, R. |
| المصدر: | Diabetes Care, DOI:10.2337/dc22-0294 (2022) |
| سنة النشر: | 2022 |
| المجموعة: | PuSH - Publikationsserver des Helmholtz Zentrums München |
| الوصف: | OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) were evaluated in a prespecified pooled analysis of these studies. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g and estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 were randomly assigned to finerenone or placebo; SGLT2is were permitted at any time. Outcomes included cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) and kidney composite (kidney failure, sustained ≥57% eGFR decline, or renal death) end points, changes in UACR and eGFR, and safety outcomes. RESULTS: Among 13,026 patients, 877 (6.7%) received an SGLT2i at baseline and 1,113 (8.5%) initiated one during the trial. For the cardiovascular composite, the hazard ratios (HRs) were 0.87 (95% CI 0.79-0.96) without SGLT2i and 0.67 (95% CI 0.42-1.07) with SGLT2i. For the kidney composite, the HRs were 0.80 (95% CI 0.69-0.92) without SGLT2i and 0.42 (95% CI 0.16-1.08) with SGLT2i. Baseline SGLT2i use did not affect risk reduction for the cardiovascular or kidney composites with finerenone (Pinteraction = 0.46 and 0.29, respectively); neither did SGLT2i use concomitant with study treatment. CONCLUSIONS: Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0149-5992 1935-5548 |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/35972218; info:eu-repo/semantics/altIdentifier/wos/undefined; info:eu-repo/semantics/altIdentifier/isbn/0149-5992; info:eu-repo/semantics/altIdentifier/piss; https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=66012Test; urn:isbn:0149-5992; urn:issn:0149-5992; urn:issn:1935-5548 |
| DOI: | 10.2337/dc22-0294 |
| الإتاحة: | https://doi.org/10.2337/dc22-0294Test https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=66012Test |
| حقوق: | info:eu-repo/semantics/embargoedAccess |
| رقم الانضمام: | edsbas.A693CC22 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 01495992 19355548 |
|---|---|
| DOI: | 10.2337/dc22-0294 |